EYPT Q3 2025 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$966,000-90.8% YoY

Gross Profit

$245,00025.4% margin

Operating Income

-$62M-6420.8% margin

Net Income

-$60M-6183.4% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

-81.9%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$60M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$252M

Total Liabilities

$52M

Stockholders' Equity

$200M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$966,000	$11M	-90.8%
Gross Profit	$245,000	$10M	-97.5%
Operating Income	-$62M	-$33M	-89.4%
Net Income	-$60M	-$29M	-103.4%

Revenue Segments

Product

$582,00060%

Royalty

$234,00024%

License And Collaboration Agreement

$150,00016%